ACW $11.1m capital raising to accelerate Alzheimers trial
Filed with ASX · · 50 pages · English
Sydney, 18 September 2024. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce the successful completion of an $8.1 million share placement to existing shareholders and new institutional investors, along with the launch of a $3.0 million share purchase plan (SPP) offer to existing shareholders on the same financial terms as the placement. The funds will be used to accelerate
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Pause in Trading
- ACW FY2024 results, advancing into late-stage trials
- ACW Appendix 4E and 2024 Annual Report
- ACW updated depression trial results and implications
- ACW XanaCIDD phase 2a trial topline results
Later from Actinogen Medical
- $3.0 million share purchase plan closes 1.3x oversubscribed
- ACW September 2024 quarterly activity report & Appendix 4C
- Actinogen receives $9.0 million R&D tax incentive rebate
- ACW randomizes first US participant in Alzheimers trial
- ACW December 2024 quarterly activity report & Appendix 4C
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical